Aptose Biosciences (APTO) Tops Q4 EPS by 3c

Note: EPS may not be comparable

Aptose Biosciences (NASDAQ: APTO) reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Aptose Biosciences (APTO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c